Editas Medicine (EDIT) Cash from Investing Activities (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Cash from Investing Activities data on file, last reported at $39.6 million in Q3 2025.

• Cash from Investing Activities for Q3 2025 came in at $39.6 million, down 52.88% year-over-year; the trailing twelve-month figure through Sep 2025 was $169.6 million (down 12.61% YoY), and the FY2024 annual result was $162.1 million, up 4445.91% from the prior year.
• Cash from Investing Activities slipped to $39.6 million in Q3 2025 per EDIT's latest filing, from $42.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $89.2 million in Q3 2022 and troughed at -$102.8 million in Q3 2023.
• A 5-year average of $18.8 million and a median of $23.3 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities surged 1637.7% in 2022, then plunged 215.23% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$22.8 million in 2021, then declined by 20.53% to -$27.5 million in 2022, then jumped by 328.28% to $62.8 million in 2023, then slumped by 50.74% to $31.0 million in 2024, then rose by 27.83% to $39.6 million in 2025.
• Business Quant data shows EDIT's Cash from Investing Activities at $39.6 million in Q3 2025, $42.6 million in Q2 2025, and $56.4 million in Q1 2025.